Mirum Pharmaceuticals (MIRM) Research & Development (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Research & Development of $97.9 million for Q1 2026, up 138.55% year-over-year from $41.0 million in Q1 2025, and up 91.58% quarter-over-quarter from $51.1 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) Research & Development (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $97.9 million for Q1 2026.
- In Q1 2026, Research & Development rose 138.55% year-over-year to $97.9 million; the TTM figure through Mar 2026 stood at $238.0 million (up 59.28% YoY), while the FY2025 annual figure was $186.2 million, up 32.39% from the prior year.
- Research & Development for Q1 2026 stood at $97.9 million, up from $51.1 million in the prior quarter.
- The five-year high for Research & Development was $97.9 million in Q1 2026, with the low at $22.0 million in Q2 2023.
- The 5-year median for Research & Development is $31.7 million (2024), against an average of $37.0 million.
- The sharpest annual moves came in 2022 and 2026: Research & Development tumbled 36.83% in 2022, then surged 138.55% in 2026.
- Mirum Pharmaceuticals' Research & Development stood at $31.1 million in 2022, then slipped by 0.55% to $30.9 million in 2023, then surged by 42.32% to $44.0 million in 2024, then climbed by 16.08% to $51.1 million in 2025, then surged by 91.58% to $97.9 million in 2026.
- Business Quant data shows MIRM's Research & Development at $97.9 million in Q1 2026, $51.1 million in Q4 2025, and $43.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | 90.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.53 Mn |
| Mar 31, 2026 | 97.91 Mn |
| Dec 31, 2025 | 51.11 Mn |
| Sep 30, 2025 | 42.96 Mn |
| Jun 30, 2025 | 46.07 Mn |
| Mar 31, 2025 | 41.04 Mn |
| Dec 31, 2024 | 44.03 Mn |
| Sep 30, 2024 | 31.71 Mn |
| Jun 30, 2024 | 32.67 Mn |
| Mar 31, 2024 | 32.22 Mn |
| Dec 31, 2023 | 30.94 Mn |
| Sep 30, 2023 | 26.12 Mn |
| Jun 30, 2023 | 22.01 Mn |
| Mar 31, 2023 | 23.55 Mn |
| Dec 31, 2022 | 31.11 Mn |
| Sep 30, 2022 | 26.22 Mn |
| Jun 30, 2022 | 25.43 Mn |
| Mar 31, 2022 | 24.09 Mn |
| Dec 31, 2021 | 27.78 Mn |
| Sep 30, 2021 | 30.47 Mn |